-
Romidepsin targets multiple survival signaling pathways in malignant T cells.
Blood cancer journal 20151001
-
Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
Chemistry & biology 20150219
-
Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes.
Molecular and cellular biology 20140401
-
Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment.
Molecular immunology 20130301
-
Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
Cancer science 20121101
-
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Molecular cancer therapeutics 20121001
-
Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
The Annals of pharmacotherapy 20121001
-
Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820
-
Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
The British journal of dermatology 20120701
-
Romidepsin for cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
-
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
Cancer investigation 20120701
-
Romidepsin for previously treated patients with peripheral or aggressive T-cell lymphomas.
Clinical advances in hematology & oncology : H&O 20120501
-
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
American journal of hematology 20120401
-
Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
Clinical journal of oncology nursing 20120401
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120220
-
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
Oncogene 20120202
-
Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
American journal of clinical dermatology 20120201
-
Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
Bioorganic & medicinal chemistry 20120115
-
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Immunology and cell biology 20120101
-
Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
Acta biochimica et biophysica Sinica 20120101
-
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Blood 20111208
-
From the observation DAC: romidepsin revisited.
Blood 20111208
-
Romidepsin in the treatment of T-cell lymphoma: profile report.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20111201
-
Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.
Journal of medicinal chemistry 20111110
-
Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.
Journal of natural products 20111028
-
Histone deacetylase inhibitors from Burkholderia thailandensis.
Journal of natural products 20111028
-
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Cell cycle (Georgetown, Tex.) 20110915
-
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.
The Journal of antibiotics 20110801
-
Romidepsin: a novel histone deacetylase inhibitor for cancer.
Expert opinion on investigational drugs 20110801
-
Romidepsin: in the treatment of T-cell lymphoma.
Drugs 20110730
-
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Journal of medicinal chemistry 20110714
-
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Journal of medicinal chemistry 20110714
-
[Epigenetic therapy in myelodysplastic syndromes].
[Rinsho ketsueki] The Japanese journal of clinical hematology 20110701
-
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood 20110602
-
Metabolism as a key to histone deacetylase inhibition.
Critical reviews in biochemistry and molecular biology 20110601
-
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Neuro-oncology 20110501
-
Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Journal of medicinal chemistry 20110414
-
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
British journal of pharmacology 20110401
-
Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin.
Fertility and sterility 20110401
-
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.
Molecular cancer research : MCR 20110401
-
Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.
Journal of cancer research and clinical oncology 20110301
-
Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death.
Molecular carcinogenesis 20110301
-
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110215
-
Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.
Analytical biochemistry 20110115
-
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Cancer 20110115
-
The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.
PloS one 20110101
-
Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
PloS one 20110101
-
Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
Fertility and sterility 20101201
-
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Expert opinion on pharmacotherapy 20101201
-
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010
-
Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
Cancer science 20101001
-
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Leukemia 20101001
-
FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death.
Anti-cancer drugs 20101001
-
Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
International journal of oncology 20101001
-
FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation.
Acta biochimica et biophysica Sinica 20101001
-
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001
-
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820
-
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Blood 20100722
-
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Expert review of anticancer therapy 20100701
-
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Cancer biology & therapy 20100601
-
Romidepsin (Istodax) for cutaneous T-cell lymphoma.
The Medical letter on drugs and therapeutics 20100531
-
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Cell cycle (Georgetown, Tex.) 20100501
-
Novel agents in development for peripheral T-cell lymphoma.
Seminars in hematology 20100401
-
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Clinical lymphoma, myeloma & leukemia 20100401
-
Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Expert review of hematology 20100401
-
Chemical phylogenetics of histone deacetylases.
Nature chemical biology 20100301
-
StatBite: FDA oncology drug product approvals in 2009.
Journal of the National Cancer Institute 20100224
-
Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
Nature reviews. Drug discovery 20100201
-
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20100115
-
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Annals of oncology : official journal of the European Society for Medical Oncology 20100101
-
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
British journal of haematology 20100101
-
New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
Journal of the American Pharmacists Association : JAPhA 20100101
-
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110
-
Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction.
Journal of cancer research and clinical oncology 20091101
-
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
Haematologica 20091101
-
Romidepsin for the treatment of cutaneous T-cell lymphoma.
Drugs of today (Barcelona, Spain : 1998) 20091101
-
Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
Chemistry (Weinheim an der Bergstrasse, Germany) 20091026
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
Investigational new drugs 20091001
-
Halogenated fatty acid amides and cyclic depsipeptides from an eastern Caribbean collection of the cyanobacterium Lyngbya majuscula.
Journal of natural products 20090901
-
Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Annals of the New York Academy of Sciences 20090801
-
New treatment strategies for Hodgkin's lymphoma.
Leukemia research 20090701
-
Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.
Leukemia research 20090701
-
An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide.
Chemistry & biology 20090626
-
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Clinical studies of histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Anti-cancer drugs 20090601
-
T-cell lymphomas.
Clinical advances in hematology & oncology : H&O 20090601
-
Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss.
Biochimica et biophysica acta 20090401
-
Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.
Journal of the American Chemical Society 20090304
-
Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
The Journal of pharmacology and experimental therapeutics 20090301
-
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
-
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201
-
[Effect of fluorouracil combined with FK228 on the proliferation, apoptosis and Fas mRNA level in HepG2 hepatoma cell lines].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20090201
-
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.
Human molecular genetics 20090115
-
Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.
International journal of cancer 20090101
-
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
PloS one 20090101
-
Development of an efficient solid-phase synthetic methodology to construct a combinatorial library of a potent HDAC inhibitor.
Advances in experimental medicine and biology 20090101
-
Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor.
The Journal of organic chemistry 20081205
-
Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents.
Journal of medicinal chemistry 20081113
-
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 20081101
-
Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
International journal of oncology 20081001
-
[Epigenetics in hematological disorders].
[Rinsho ketsueki] The Japanese journal of clinical hematology 20081001
-
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Cancer biology & therapy 20080901
-
[How and why was a histone deacetylase inhibitor created?].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080901
-
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
Journal of the American Chemical Society 20080820
-
Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.
Journal of proteome research 20080701
-
[FK228 promotes the IL-3 mediated proliferation and differentiation of human erythroid progenitor cells].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20080701
-
Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma.
The Journal of investigative dermatology 20080601
-
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Cancer research 20080601
-
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Molecular cancer therapeutics 20080601
-
Inhibition of histone deacetylase1 induces autophagy.
Biochemical and biophysical research communications 20080516
-
Instability of retroviral DNA methylation in embryonic stem cells.
Stem cells (Dayton, Ohio) 20080501
-
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
Molecular cancer therapeutics 20080501
-
Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401
-
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Molecular cancer therapeutics 20080401
-
The depsipeptide technique applied to peptide segment condensation: scope and limitations.
Journal of peptide science : an official publication of the European Peptide Society 20080301
-
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Expert review of anticancer therapy 20080301
-
Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228).
Organic letters 20080221
-
Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080215
-
Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080201
-
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080201
-
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080115
-
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080101
-
Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080101
-
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
Molecular cancer research : MCR 20080101
-
Depsipeptide (FK228) inhibits growth of human prostate cancer cells.
Urologic oncology 20080101
-
Histone deacetylase inhibitors from microorganisms: the Astellas experience.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20080101
-
Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.
Anticancer research 20080101
-
Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells.
Journal of immunology (Baltimore, Md. : 1950) 20071215
-
Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
Urology 20071201
-
The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
Journal of medicinal chemistry 20071115
-
Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells.
Journal of cancer research and clinical oncology 20071001
-
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity.
Mini reviews in medicinal chemistry 20071001
-
Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
Oncology reports 20070901
-
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Cell death and differentiation 20070801
-
Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Urology 20070801
-
[EPO mediated proliferation and differentiation of human erythroid progenitor inhibited by FK228].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20070601
-
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Stem cells and development 20070601
-
FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.
Biochemical and biophysical research communications 20070518
-
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Cancer biology & therapy 20070501
-
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
International journal of cancer 20070415
-
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Oncology reports 20070401
-
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Cancer gene therapy 20070301
-
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
The Journal of urology 20070301
-
Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells.
Molecular cancer therapeutics 20070301
-
[Fermentation research on natural products derived from micro-organisms for the discovery of new drugs].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070301
-
Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Chemico-biological interactions 20070220
-
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Investigational new drugs 20070201
-
HDAC inhibitors and cardiac safety.
Clinical cancer research : an official journal of the American Association for Cancer Research 20070201
-
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Molecular cancer therapeutics 20070201
-
[The inhibitory effects of FK228 on retinal neovascularization].
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20070201
-
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Cancer letters 20070108
-
The histone deacetylase inhibitor FK228 may have therapeutic usefulness to prevent suicidal behaviour via upregulation of the guanosine triphosphatase Rap-1.
Medical hypotheses 20070101
-
Utilization of chromatin remodeling agents for lung cancer therapy.
Cancer journal (Sudbury, Mass.) 20070101
-
Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?
Cancer journal (Sudbury, Mass.) 20070101
-
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Cancer journal (Sudbury, Mass.) 20070101
-
Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.
Gene therapy 20061201
-
Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
American journal of hematology 20061201
-
The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
Annals of the New York Academy of Sciences 20061201
-
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Cancer chemotherapy and pharmacology 20061101
-
Targeting the epigenome for the treatment of thoracic malignancies.
Thoracic surgery clinics 20061101
-
Targeting of interstitial cells using a simple gene-transfer strategy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061001
-
Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.
British journal of haematology 20061001
-
Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation.
Apoptosis : an international journal on programmed cell death 20060801
-
Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.
International journal of radiation oncology, biology, physics 20060701
-
Cardiac safety, risk management, and oncology drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 20060615
-
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20060615
-
Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile.
Leukemia research 20060601
-
Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein.
Leukemia research 20060601
-
Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Cancer research 20060601
-
Histone post-translational modification: from discovery to the clinic.
IDrugs : the investigational drugs journal 20060601
-
A phase II study of depsipeptide in refractory metastatic renal cell cancer.
Clinical genitourinary cancer 20060601
-
A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells.
Molecular therapy : the journal of the American Society of Gene Therapy 20060401
-
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Clinical cancer research : an official journal of the American Association for Cancer Research 20060301
-
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
Blood 20060215
-
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Experimental cell research 20060201
-
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Oncogene 20060126
-
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.
Cell death and differentiation 20060101
-
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
International journal of cancer 20060101
-
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Acta haematologica 20060101
-
Histone deacetylase inhibitors in cancer therapy.
Cancer investigation 20060101
-
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Cancer research 20051201
-
Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.
Haematologica 20051201
-
Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production.
Journal of immunology (Baltimore, Md. : 1950) 20051101
-
Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20051101
-
Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.
International journal of cancer 20050920
-
A putative role for histone deacetylase in the differentiation of human erythroid cells.
International journal of oncology 20050901
-
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Cancer biology & therapy 20050901
-
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Cancer research 20050815
-
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
The Journal of urology 20050801
-
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Cancer research 20050715
-
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.
Oncogene 20050714
-
Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.
Cancer chemotherapy and pharmacology 20050701
-
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
The Journal of pharmacology and experimental therapeutics 20050701
-
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Cancer letters 20050628
-
Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Journal of cellular physiology 20050501
-
Interference of CREB-dependent transcriptional activation by expanded polyglutamine stretches--augmentation of transcriptional activation as a potential therapeutic strategy for polyglutamine diseases.
Journal of neurochemistry 20050501
-
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.
Cell cycle (Georgetown, Tex.) 20050501
-
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
The Journal of pharmacology and experimental therapeutics 20050401
-
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Molecular therapy : the journal of the American Society of Gene Therapy 20050401
-
Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.
Cancer biology & therapy 20050401
-
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
Oncogene 20050331
-
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
Postepy higieny i medycyny doswiadczalnej (Online) 20050311
-
Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Oncology reports 20050301
-
Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.
Biochemical pharmacology 20050215
-
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Blood 20050201
-
Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228.
FEBS letters 20050103
-
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.
Cell death and differentiation 20050101
-
Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes.
Biological & pharmaceutical bulletin 20050101
-
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
Molecular cancer therapeutics 20041101
-
[A histone deacetylase inhibitor and tumor suppressing gene p53 induction synergistically induce apoptosis of cancer cells].
[Hokkaido igaku zasshi] The Hokkaido journal of medical science 20041101
-
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Journal of the National Cancer Institute 20041006
-
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Arthritis and rheumatism 20041001
-
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925
-
Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants.
The Journal of endocrinology 20040901
-
[Violacein: a molecule of biological interest originating from the soil-borne bacterium Chromobacterium violaceum].
La Revue de medecine interne 20040901
-
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
Cancer chemotherapy and pharmacology 20040701
-
Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Oral oncology 20040701
-
Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.
International journal of cancer 20040610
-
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Endocrinology 20040601
-
Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
Acta neuropathologica 20040601
-
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Radiation research 20040601
-
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040601
-
Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression.
The journal of gene medicine 20040501
-
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
British journal of haematology 20040401
-
FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
International journal of oncology 20040301
-
Genomic surgery for lung cancer.
The Journal of surgical research 20040301
-
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040301
-
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Anticancer research 20040101
-
A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.
Current pharmaceutical design 20040101
-
Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Anticancer research 20040101
-
FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
Oncogene 20031218
-
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20031101
-
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Biochemical pharmacology 20030915
-
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Cancer research 20030801
-
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Blood 20030715
-
Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Cancer letters 20030610
-
Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Investigative ophthalmology & visual science 20030601
-
Histone deacetylase inhibitors activate p21(WAF1) expression via ATM.
Cancer research 20030601
-
Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Leukemia research 20030501
-
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
The Journal of thoracic and cardiovascular surgery 20030501
-
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
International journal of cancer 20030320
-
Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Anti-cancer drugs 20030301
-
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
Cancer gene therapy 20030301
-
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Leukemia 20030201
-
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity.
Biochemical and biophysical research communications 20030103
-
Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.
Rapid communications in mass spectrometry : RCM 20030101
-
Profiling of cyclic hexadepsipeptides roseotoxins synthesized in vitro and in vivo: a combined tandem mass spectrometry and quantum chemical study.
European journal of mass spectrometry (Chichester, England) 20030101
-
Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Biochemical pharmacology 20021001
-
A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.
The Journal of clinical endocrinology and metabolism 20021001
-
FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Oncogene 20020912
-
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.
Cancer research 20020901
-
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
Molecular cancer therapeutics 20020901
-
FR-901228 Fujisawa/National Cancer Institute.
Current opinion in investigational drugs (London, England : 2000) 20020901
-
38th annual meeting of the American Society of Clinical Oncology.
Clinical lymphoma 20020601
-
Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells.
European journal of immunology 20020401
-
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Blood 20020315
-
Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228.
The Journal of pharmacology and experimental therapeutics 20020301
-
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 20020301
-
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 20020301
-
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
International journal of cancer 20020120
-
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
Journal of experimental therapeutics & oncology 20020101
-
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
Blood 20011101
-
Inhibitors of histone deacetylase as new anticancer agents.
Current medicinal chemistry 20011001
-
Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
Cancer research 20010901
-
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
The Journal of clinical endocrinology and metabolism 20010701
-
In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Japanese journal of cancer research : Gann 20010501
-
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
The Journal of clinical endocrinology and metabolism 20010201
-
Induction of MAGE-3 expression in lung and esophageal cancer cells.
The Annals of thoracic surgery 20010101
-
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Journal of immunotherapy (Hagerstown, Md. : 1997) 20010101